Previous 10 | Next 10 |
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage oncology focused biotechnology company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported new preclinical data on CTX-8371, a next generati...
Gainers: Sunshine Biopharma (SBFM) +132%. Dingdong Limited (DDL) +29%. System1 (SST) +27%. FG Financial Group (FGF) +25%. Missfresh (MF) +21%. BT Brands (BTBD) +20%. Longeveron (LGVN) +18%. Compass Therapeutics (CMPX) +18%. Allego (ALLG) +17%. Nam Tai Property (NTP) +15%. Losers: IMARA (IMRA)...
BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biotechnology company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced today that it will present preclinical data on CTX-837...
Compass Therapeutics press release (NASDAQ:CMPX): Q4 GAAP EPS of -$0.15 misses by $0.08. cash and cash equivalents of $144.5M as of December 31, 2021 Shares +1.54% PM. For further details see: Compass Therapeutics GAAP EPS of -$0.15 misses by $0.08
Ended 2021 with $144.5 million in cash and cash equivalents CTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced biliary tract cancers (BTC) is progressing well; the response criteria required to advance the study to its second stage have been met...
BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its IND applicatio...
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that Thomas Schuetz, M.D., Ph.D., Co-founder and Chief Executive Officer, will present a company update at the 40 t...
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced Thomas J. Schuetz, MD, PhD, Co-founder, and Chief Executive Officer is presenting at the Piper Sandler 33 rd Annu...
Do you follow the money when you’re looking for penny stocks to buy ? In many cases, anyone putting together a list of stocks to watch for longer than a day is looking at more than just technical indicators. Sure, these low-priced names are well known for their ability to break o...
Compass Therapeutics (NASDAQ:CMPX): Q3 GAAP EPS of -$0.10. As of Sep.30, cash and equivalents stood at $25.5M compared to $47.1M as of Dec.31, 2020. For further details see: Compass Therapeutics reports Q3 results
News, Short Squeeze, Breakout and More Instantly...
Compass Therapeutics Inc. Company Name:
CMPX Stock Symbol:
OTCMKTS Market:
Compass Therapeutics Inc. Website:
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside cha...
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Sc...
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors....